Fulcrum Therapeutics, Inc. (FULC) AI Stock Analysis

Fulcrum Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical firm dedicated to developing therapies for genetically defined diseases with significant unmet medical needs. Its pipeline focuses on rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Key product candidates include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058, an oral fetal hemoglobin inducer for sickle cell disease and beta-thalassemia. Fulcrum collaborates with industry partners, including research partnerships with Acceleron Pharma Inc. for pulmonary targets and a collaboration and license agreement with MyoKardia, Inc. for genetic cardiomyopathies.

Between FY2020 and FY2024, Fulcrum's top line experienced substantial volatility, recording a 5-year revenue CAGR of 154.5%. Revenue registered at $8.8M in FY2020, rose to $19.2M in FY2021, fell to $6.3M in FY2022 and $2.8M in FY2023, before surging 2752.0% to $80.0M in FY2024. Operating margins remained negative throughout the period, finishing at -27.4% in FY2024 alongside net income of -$9.7M. For the trailing twelve months ending June 30, 2026, revenue fell to $0, representing a quarterly revenue decline of 100.0% year-over-year and an EPS TTM of -$1.21.

As of June 30, 2026, Fulcrum held $318.8M in cash and short-term investments against $5.3M in total debt, resulting in net cash of $313.6M. The company maintains a current ratio of 31.35 and a debt-to-equity ratio of 0.02. In FY2024, operating cash flow was -$2.2M and free cash flow was -$2.5M. Cash usage included capital expenditures of $314,000 in FY2025, while its share count expanded 87.9% over a 5-year period.

Fulcrum trades at a market cap of $278.8M and an enterprise value of -$22.9M. Its price-to-sales ratio is 2.7x, below the median of its US-listed Healthcare peers of 4.1x, and it holds a price-to-book ratio of 0.9x. The stock has underperformed broader benchmarks, declining 60.7% over the past year compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock fell 86.0%, while the S&P 500 returned 83.0%.

Analyst coverage consists of 0 Strong Buy, 0 Buy, 4 Hold, 1 Sell, and 0 Strong Sell ratings. The mean price target is $3.67, which represents a 0.5% premium over the last close of $3.65 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates anticipate revenue of $0 and an EPS of -$0.66. Fulcrum has beaten EPS estimates in 1 of the last 4 quarters, with its next earnings announcement scheduled for November 4, 2026.

This page is an AI-written research summary of Fulcrum Therapeutics, Inc. (FULC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: FULC income statement, FULC balance sheet, FULC key metrics, FULC analyst forecast, FULC chart. See the FULC stock overview for the latest quote and news.